Publications by authors named "K Dubravcic"
Article Synopsis
- - Monitoring minimal residual disease (MRD) through flow cytometry (FCM) is essential for predicting outcomes in acute lymphoblastic leukemia (ALL), but requires skilled laboratory personnel and ongoing quality checks.
- - The international Berlin-Frankfurt-Münster (I-BFM) consortium created a comprehensive training and quality control program to standardize FCM-MRD practices across multiple reference labs.
- - Key elements of this program include a twinning maturation program, mandatory external quality assessments, regular data trials, and independent survey evaluations, resulting in significantly improved accuracy and consistency in MRD detection in pediatric ALL patients.
All-trans retinoic acid (ATRA)-based therapy for acute promyelocytic leukemia (APL), a subtype of acute myeloid leukemia (AML), is the most successful example of differentiation therapy. Although ATRA can induce differentiation in some non-APL AML cell lines and primary blasts, clinical results of adding ATRA to standard therapy in non-APL AML patients have been inconsistent, probably due to use of different regimens and lack of diagnostic tools for identifying which patients may be sensitive to ATRA. In this study, we exposed primary blasts obtained from non-APL AML patients to ATRA to test for differentiation potential in vitro.
View Article and Find Full Text PDFBackground: All-trans retinoic acid (ATRA)-based treatment of acute promyelocytic leukemia (APL) is the most successful pharmacological treatment of acute myeloid leukemia (AML). Recent development of inhibitors of mutated isocitrate dehydrogenase and dihydroorotate dehydrogenase (DHODH) has revived interest in differentiation therapy of non-APL AML. Our previous studies demonstrated that 5-aminoimidazole-4-carboxamide ribonucleoside (AICAr) induced differentiation of monocytic cell lines by activating the ATR/Chk1 via pyrimidine depletion.
View Article and Find Full Text PDFThis report describes a case of maternal-foetal chimerism identified in a boy diagnosed with SCID, who underwent HLA testing in preparation for HSCT. The first analysis was carried out on DNA from peripheral blood and included HLA-A, HLA-B, HLA-DRB1 typing using PCR-SSO. The patient's HLA-B typing results were noninterpretable.
View Article and Find Full Text PDFAim: To evaluate the clinical utility of incorporating a novel heavy/light chain immunoassay (HLC) into the existing methods for the assessment of multiple myeloma (MM) patients.
Methods: Convenience sera samples from 90 previously treated IgG and IgA MM patients in different disease stages were analyzed. The study was conducted in Clinical Hospital Center Zagreb between 2011 and 2013.